Back to Authors

Cazzola, Mario

0000-0001-6984-8817

Mayo Clinic

Division of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.

Citations 11

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Passamonti, Francesco , Cervantes, Francisco , Morra, Enrica, Rumi, Elisa , Pereira, Arturo , Guglielmelli, Paola , Pungolino, Ester , Caramella, Marianna, Maffioli, Margherita , Pascutto, Cristiana, Lazzarino, Mario, Cazzola, Mario , Tefferi, Ayalew , Vannucchi, Alessandro M. , Passamonti, Francesco , Cazzola, Mario , Guglielmelli, Paola

Blood | December 14, 2009 | Volume: 115 | Issue: 9 | Pages: 1703-1708

10.1182/blood-2009-09-245837 Get It

Abstract Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 × 109/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.